$IGC

IGC Pharma (NYSE American: IGC) said it is evaluating potential civil remedies after a federal jury verdict in United States v. Andrew Left found Left guilty of securities fraud. The indictment named IGC in an alleged 2018 short campaign. IGC will assess possible recoverable damages, including market value, reputational and operational harm, and legal costs. The SEC said Anson Advisors paid $2.25M in penalties tied to trading profits.

IGC Pharma, Inc. (IGC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001326205 0001326205 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Repor

IGC Pharma (NYSE American:IGC) said its beta Agentic Harmonization Assistant (AHA) is designed to speed harmonization of fragmented Alzheimer’s datasets. In internal testing on a 100-variable workflow, it cut time from 28 hours to 2.5 hours (90% reduction). The company plans to demonstrate AHA at AAIC 2026 in London and is advancing Phase 2 CALMA for IGC-AD1.

IGC Pharma, Inc. (IGC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001326205 0001326205 2026-06-05 2026-06-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Repor

New to The Street said its Bloomberg Television sponsored program airs May 30 at 6:30 PM ET, featuring interviews with executives across AI, healthcare, fintech, digital assets and commodities. Among guests: YesSmile.ai (AI for dental admin in a $200B market), Lantern Pharma (Zeta for rare cancers), Roadzen (AI for auto insurance), and Gold Royalty Corp. (250+ royalties/streams).

IGC Pharma, Inc. CEO Mukunda Ram acquired a total of 706,409 shares of common stock on April 1, 2026, through the exercise of restricted stock units and stock options. These transactions are described as routine compensation-related vesting and option exercises, not discretionary buying or selling. Following these acquisitions, Ram directly holds 4,649,088 shares, with an additional 910,751 shares held indirectly by his spouse.

IGC Pharma announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for patent No. 3,095,729, protecting the proprietary composition of IGC-AD1, their Phase 2 clinical stage program for agitation in Alzheimer's disease. This secures North American composition protection for IGC-AD1, reinforcing its long-term exclusivity as enrollment for the Phase 2 CALMA trial approaches completion. The company emphasized that this intellectual property strengthening enhances the durability and commercial positioning of IGC-AD1, which is a low-dose THC formulation combined with other ingredients.

IGC Pharma announced that it has secured North American composition protection for its low-dose THC Alzheimer's drug, IGC-AD1, following a Notice of Allowance from the Canadian Intellectual Property Office. This patent covers the specific formulation as its Phase 2 CALMA trial, targeting agitation in Alzheimer's disease, approaches 70% enrollment completion. The company believes this strengthens the long-term exclusivity and commercial positioning of IGC-AD1.

IGC Pharma, Inc. (NYSE American:IGC) announced that Alliance Global Partners (AGP) has published an updated equity research report. The report reiterates a Buy rating for IGC Pharma and sets a price target of $3.00 per share. IGC Pharma emphasizes that the report's views are solely those of the analysts and not endorsed by the company.

IGC Pharma, Inc. (IGC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.